U.S. Markets open in 7 hrs 4 mins

Keryx, Upcoming PDUFA Action on Label Expansion for Auryxia

NEW YORK, NY / ACCESSWIRE / October 5, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies, is issuing a comprehensive report with no obligation on Keryx Biopharmaceuticals, Inc. (KERX), a commercial-stage company focused on bringing innovative medicines to people with renal disease.

The company is poised for a Label Expansion Opportunity. A supplemental new drug application seeking approval of Auryxia for the treatment of patients with iron deficiency anemia and non-dialysis dependent chronic kidney disease is currently under FDA review.

Currently, there is no FDA approved oral treatment to treat iron deficiency in non-dialysis-dependent chronic kidney disease.

Get the details of the upcoming PDUFA action for Auryxia here: READ MORE.

Copy and paste to your browser may be required to view the report - http://tradersnewssource.com/keryx/.

Auryxia has already presented encouraging results in a pivotal Phase 3 trial where it showed statistically significant differences over placebo for the primary and secondary endpoints and potential FDA approval could help in expanding the addressable market for the drug as it will then be able to cover the NDD market, which consists of patients who are not yet required to be put on dialysis, or the stage which is referred to as End Stage Kidney Disease (ESKD).

Iron deficiency anemia is a severe disease and, today, as many as three out of four people with chronic kidney disease, and iron deficiency anemia, are not being optimally treated with existing iron supplements.

Get the KERX guidance for 2017, the outlook for Auryxia, and financial review here: READ MORE.

Copy and paste to your browser may be required to view the report - http://tradersnewssource.com/keryx/.


Traders News Source LLC ("TNS") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

TNS has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, for further information on analyst credentials, please email editor@tradersnewssource.com. Vikas Agrawal, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: editor@tradersnewssource.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.



SOURCE: Traders News Source